Views & Analysis The UK general election: what pharma wants As the UK election approaches how do the main parties measure up regarding health funding?
News Labour's tax rises could damage economy, says UK pharma Corporation tax increase could damage UK's competitiveness, says ABPI
Views & Analysis Partnerships can drive more early-stage assets into clinical... Investors who see early-stage compounds and indications as valuable assets can support them to market.
Views & Analysis Novartis: UK market access starting to resemble austerity-hi... The new head of Novartis UK thinks the country has gone backwards in terms of access to medicines.
Views & Analysis Pharmacovigilance as a business enabler Industry may be limiting its options if safety takes a back seat to efficacy in trial design and product development.
News Ipsen' Bylvay fluffs its lines in biliary atresia trial Ipsen's IBAT inhibitor Bylvay has failed a trial in biliary atresia, a rare and serious liver disease that affects babies and has limited treatments.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
